Abstract: Provided herein are populations of placental-derived natural killer cells comprising a cleavage resistant CD16. Also provided are methods of treating diseases, disorders or conditions in a human subject comprising administering to the subject an effective amount of a population of placental-derived natural killer cells comprising a cleavage resistant CD16 to the subject so as thereby to provide an effective treatment of the to the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The diseases, disorders or conditions include cancers such as multiple myeloma and lymphoma. The present invention also provides compositions comprising populations of placental-derived natural killer cells comprising a cleavage resistant CD16 for the treatment of a subject and methods of their use.

Abstract: Systems and methods for reducing network traffic by filtering network requests based on network request-related information to be transmitted to one or more remote computing systems are disclosed. The system receives a first network operation indicating (i) a request to access a first resource and (ii) a set of requestor specific criteria associated with accessing the first resource. The system identifies a set of entities associated with the first resource and selectively communicates with a filtered subset of the set of entities by: identifying a set of entity specific criteria for each entity of the set of entities; determining whether the requestor specific criteria satisfies the set of entity specific criteria of respective entities; and transmitting the first network operation to respective entities in response to the requestor specific criteria satisfying the set of entity specific criteria of the respective entity.

Abstract: Provided herein are methods of treating cancer in a human subject comprising administering to the subject an effective amount of human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) to the subject so as thereby to provide an effective treatment of the cancer in the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The cancers to be treated include multiple myeloma and lymphoma. The present invention also provides compositions comprising human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) or the treatment of multiple myeloma and lymphoma and methods of their use.